V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Bristol Myers Squibb Executive Compensation (FY25)

BMY · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): May 8, 2026
303 figures on this page: 296 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
Total compensation for Christopher Boerner, Board Chair and Chief Executive Officer, came to $21,879,919 in fiscal 2025, and Boerner's total was 16.5% higher than the $18,787,618 reported for fiscal 2024. For fiscal 2025, the company reported a chief executive pay ratio of 131:1, against median employee compensation of $167,191. For fiscal 2025, shareholders backed the say-on-pay proposal with 94.8% of votes cast including abstentions in favor at the meeting held May 5, 2026. Companies named in the disclosed peer group include AbbVie Inc., Amgen Inc., Eli Lilly and Company, Gilead Sciences and Johnson & Johnson, among others.
Chief executive, fiscal 2025
◇
Christopher Boerner
Median of the other named officers
$9,340,352
5 officers, excluding the chief executive
Latest say-on-pay support
=
May 5, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Christopher Boerner: $18,787,618 → $21,879,919 (16.5% higher)
CEO pay ratio: 117:1 → 131:1 (12.0% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Bristol Myers Squibb's chief executive and what were they paid?
Total compensation for Christopher Boerner, Board Chair and Chief Executive Officer, came to $21,879,919 in fiscal 2025. Boerner's total was 16.5% higher than the $18,787,618 reported for fiscal 2024.
What was Bristol Myers Squibb's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 94.8% of votes cast including abstentions in favor at the meeting held May 5, 2026.
Which companies are in Bristol Myers Squibb's peer group?
Companies named in the disclosed peer group include AbbVie Inc., Amgen Inc., Eli Lilly and Company, Gilead Sciences and Johnson & Johnson, among others. The Extended Peer Group names AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, Roche Holding AG and Sanofi.
What is Bristol Myers Squibb's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 131:1, against median employee compensation of $167,191.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Giovanni Caforio
Executive Chair and Former Chief Executive Officer
◇—◇—◇—◇◇
David Elkins
EVP and Chief Financial Officer
◇—◇—◇—◇◇
Christopher Boerner
Board Chair and Chief Executive Officer
◇—◇—◇—◇◇
Sandra Leung
EVP and General Counsel
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Giovanni Caforio
Executive Chair and Former Chief Executive Officer
Departed during or after this year
◇—◇—◇—◇◇
Christopher Boerner
Board Chair and Chief Executive Officer
◇—◇—◇—◇◇
David Elkins
EVP and Chief Financial Officer
◇—◇—◇—◇◇
Samit Hirawat
Former EVP, Chief Medical Officer, Head of Development
◇—◇—◇—◇◇
Sandra Leung
EVP and General Counsel
◇—◇—◇—◇◇
Elizabeth Mily
EVP, Strategy & Business Development
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Boerner
Board Chair and Chief Executive Officer
◇—◇—◇—◇◇
David Elkins
EVP and Chief Financial Officer
◇—◇—◇—◇◇
Samit Hirawat
Former EVP, Chief Medical Officer, Head of Development
◇—◇—◇—◇◇
Sandra Leung
EVP and General Counsel
◇—◇—◇—◇◇
Karin Shanahan
EVP, Global Product Development & Supply
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Boerner
Board Chair and Chief Executive Officer
◇—◇—◇—◇◇
Samit Hirawat
Former EVP, Chief Medical Officer, Head of Development
Departed during or after this year
◇—◇—◇—◇◇
Cristian Massacesi
EVP, Chief Medical Officer, Head of Development
◇◇◇—◇—◇◇
Adam Lenkowsky
EVP, Chief Commercialization Officer
◇—◇—◇◇◇◇
David Elkins
EVP and Chief Financial Officer
◇—◇—◇—◇◇
Greg Meyers
EVP and Chief Digital & Technology Officer
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Adam LenkowskyPSU—◇◇—◇—◇
Adam LenkowskyRSU———◇——◇
Adam LenkowskyPSU——◇—◇—◇
Christopher BoernerPSU—◇◇—◇—◇
Christopher BoernerPSU——◇—◇—◇
Cristian MassacesiRSU———◇——◇
David ElkinsPSU—◇◇—◇—◇
David ElkinsPSU——◇—◇—◇
Greg MeyersPSU——◇—◇—◇
Greg MeyersPSU—◇◇—◇—◇
Samit HirawatPSU—◇◇—◇—◇
Samit HirawatPSU——◇—◇—◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Adam LenkowskyRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
David ElkinsRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Samit HirawatRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Christopher BoernerRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Greg MeyersRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Cristian MassacesiRSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Theodore R. Samuels
Lead independent director
◇◇———◇◇
Derica W. Rice
◇◇———◇◇
Julia A. Haller, M.D
◇◇———◇◇
Paula A. Price
◇◇———◇◇
Michael R. McMullen
◇◇———◇◇
Peter J. Arduini
◇◇———◇◇
Phyllis R. Yale
◇◇———◇◇
Karen H. Vousden, Ph.D
◇◇———◇◇
Manuel Hidalgo Medina, M.D., Ph.D
◇◇————◇
Deepak L. Bhatt, M.D., M.P.H., M.B.A
◇◇————◇
Christopher S. Boerner, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Deferred Share Units.
Stock ownership guideline: 5x annual cash retainer ($550,000)

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • AbbVie Inc. ABBV
  • Amgen Inc. AMGN
  • Eli Lilly and Company LLY
  • Gilead Sciences GILD
  • Johnson & Johnson JNJ
  • Merck & Co. MRK
  • Pfizer Inc. PFE
  • Regeneron Pharmaceuticals REGN
Extended Peer Group
  • AstraZeneca PLC AZN
  • GlaxoSmithKline PLC GSK
  • Novartis AG NVS
  • Roche Holding AG symbol not shown
  • Sanofi SNY
PHRA Survey Group
  • Takeda Pharmaceutical Co. TAK

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 5, 2026=◇◇◇
2024May 6, 2025=◇◇◇
2023May 7, 2024=◇◇◇
2022May 2, 2023=◇◇◇
2021May 3, 2022=◇◇◇
2020May 4, 2021=◇◇◇
2018May 29, 2019=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Bristol Myers Squibb files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Bristol Myers Squibb disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Bristol Myers Squibb sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Bristol Myers Squibb's disclosed peer group is defensible, who names Bristol Myers Squibb back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
303 figures on this page: 296 cited to the filing that reported them, 7 calculated from figures it prints.
296 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001140361-26-020036
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0000014272-26-000006
    Director Compensation Table · Executive Compensation Tables · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year-End · and 1 more section
  3. 0001140361-25-017742
  4. 0000014272-25-000075
    Executive Compensation Tables
  5. 0001140361-24-025213
  6. 0001140361-24-016251
    Summary Compensation Table
  7. 0001140361-23-022991
  8. 0001140361-23-013442
    Summary Compensation Table
  9. 0001140361-22-017866
  10. 0001140361-21-016224
  11. 0001140361-19-010115
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Bristol Myers Squibb executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/BMY (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Bristol Myers Squibb and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Bristol Myers Squibb discloses

The companies named in BMY's own disclosed peer group.

AbbVie Inc.Amgen Inc.Eli Lilly and CompanyGilead SciencesJohnson & JohnsonMerck & Co.Pfizer Inc.Regeneron Pharmaceuticals

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy